Carmen Gil

Carmen Gil

Auto-generated profile, based on publicly available information

Carmen Gil

Instituto de Agrobiotecnología, CSIC-Universidad Pública Navarra-Gobierno Navarra, Mutilva, Spain

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2012 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
JVJaione Valle
Jaione Valle
CLCristina Latasa
Cristina Latasa
CGCarmen Gil
Carmen Gil
ATAlejandro Toledo-Arana
Alejandro Toledo-Arana
CSCristina Solano
Cristina Solano
ILIñigo Lasa
Iñigo Lasa
The biofilm matrix, composed of exopolysaccharides, proteins, nucleic acids and lipids, plays a well-known role as a defence structure, protecting bacteria from the host immune system and antimicrobial therapy. However, little is known about its responsibility in the interaction of biofilm cells with host tissues. Staphylococcus aureus, a leading cause of biofilm-associated chronic infections, is able to develop a biofilm built on a proteinaceous Bap-mediated matrix. Here, we used the Bap protein as a model to investigate the role that components of the biofilm matrix play in the interaction of S. aureus with host cells. The results show that Bap promotes the adhesion but prevents the entry of S. aureus into epithelial cells. A broad analysis of potential interaction partners for Bap using ligand overlayer immunoblotting, immunoprecipitation with purified Bap and pull down with intact bacteria, identified a direct binding between Bap and Gp96/GRP94/Hsp90 protein. The interaction of Bap with Gp96 provokes a significant reduction in the capacity of S. aureus to invade epithelial cells by interfering with the fibronectin binding protein invasion pathway. Consistent with these results, Bap deficient bacteria displayed an enhanced capacity to invade mammary gland epithelial cells in a lactating mice mastitis model. Our observations begin to elucidate the mechanisms by which components of the biofilm matrix can facilitate the colonization of host tissues and the establishment of persistent infections. Staphylococcus aureus is a pathogen responsible for a wide variety of infections, some of which become chronic due to the capacity of this bacteria to form multicellular communities that grow embedded in a self-produced extracellular matrix, referred to as biofilms. Numerous evidences have demonstrated that growing in the biofilm protects bacteria from the immune system and antimicrobial treatments. However, less attention has been paid to the role that the biofilm extracellular matrix plays in the interaction with host cells. Here, we investigate this issue through the use of the proteinaceous biofilm matrix assembled by the Bap protein as a model. Our results show that the Bap biofilm matrix triggers the adhesion to epithelial cells. After adhesion, Bap binds directly to the host receptor Gp96 and this interaction inhibits the entry of the bacteria into the cells by interfering with the fibronectin-binding protein mediated invasion pathway. As a result, the expression of Bap decreased cell invasion and increased bacterial persistence in lactating mice mammary glands. Thus, our findings revealed a dual role for the Bap‐dependent biofilm matrix during the establishment of persistent infections, promoting adhesion of S. aureus to epithelial cells and impairing host cell invasion.

27 April 2015 in Macromolecular Bioscience
Verified
Journal Article
Closed access
PDF file
JVJaione Valle
Jaione Valle
SBSaioa Burgui
Saioa Burgui
DLDenise Langheinrich
Denise Langheinrich
CGCarmen Gil
Carmen Gil
CSCristina Solano
Cristina Solano
ILIñigo Lasa
Iñigo Lasa

1 March 2014 in Infection and Immunity
Verified
Journal Article
Closed access
CGCarmen Gil
Carmen Gil
CSCristina Solano
Cristina Solano
SBSaioa Burgui
Saioa Burgui
CLCristina Latasa
Cristina Latasa
BGBegoña García
Begoña García
JVJaione Valle
Jaione Valle
TheStaphylococcus aureusbiofilm mode of growth is associated with several chronic infections that are very difficult to treat due to the recalcitrant nature of biofilms to clearance by antimicrobials. Accordingly, there is an increasing interest in preventing the formation ofS. aureusbiofilms and developing efficient antibiofilm vaccines. Given the fact that during a biofilm-associated infection, the first primary interface between the host and the bacteria is the self-produced extracellular matrix, in this study we analyzed the potential of extracellular proteins found in the biofilm matrix to induce a protective immune response againstS. aureusinfections. By using proteomic approaches, we characterized the exoproteomes of exopolysaccharide-based and protein-based biofilm matrices produced by two clinicalS. aureusstrains. Remarkably, results showed that independently of the nature of the biofilm matrix, a common core of secreted proteins is contained in both types of exoproteomes. Intradermal administration of an exoproteome extract of an exopolysaccharide-dependent biofilm induced a humoral immune response and elicited the production of interleukin 10 (IL-10) and IL-17 in mice. Antibodies against such an extract promoted opsonophagocytosis and killing ofS. aureus. Immunization with the biofilm matrix exoproteome significantly reduced the number of bacterial cells inside a biofilm and on the surrounding tissue, using anin vivomodel of mesh-associated biofilm infection. Furthermore, immunized mice also showed limited organ colonization by bacteria released from the matrix at the dispersive stage of the biofilm cycle. Altogether, these data illustrate the potential of biofilm matrix exoproteins as a promising candidate multivalent vaccine againstS. aureusbiofilm-associated infections.

4 July 2015 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
LALeire Aguinagalde
Leire Aguinagalde
RDRoberto Diez-Martinez
Roberto Diez-Martinez
JYJose Yuste
Jose Yuste
IRInmaculada Royo
Inmaculada Royo
CGCarmen Gil
Carmen Gil
JSJosé María Sanchez-Puelles
José María Sanchez-Puelles
Auranofin is an FDA-approved, gold-containing compound in clinical use for the oral treatment of rheumatoid arthritis and has been recently granted by the regulatory authorities due to its antiprotozoal properties. A reprofiling strategy was performed with a Streptococcus pneumoniae phenotypic screen and a proprietary library of compounds, consisting of both FDA-approved and unapproved bioactive compounds. Two different multiresistant S. pneumoniae strains were employed in a sepsis mouse model of infection. In addition, an MRSA strain was tested using both the thigh model and a mesh-associated biofilm infection in mice. The repurposing approach showed the high potency of auranofin against multiresistant clinical isolates of S. pneumoniae and Staphylococcus aureus in vitro and in vivo. Efficacy in the S. pneumoniae sepsis model was obtained using auranofin by the oral route in the dose ranges used for the treatment of rheumatoid arthritis. Thioglucose replacement by alkyl chains showed that this moiety was not essential for the antibacterial activity and led to the discovery of a new gold derivative (MH05) with remarkable activity in vitro and in vivo. Auranofin and the new gold derivative MH05 showed encouraging in vivo activity against multiresistant clinical isolates of S. pneumoniae and S. aureus. The clinical management of auranofin, alone or in combination with other antibiotics, deserves further exploration before use in patients presenting therapeutic failure caused by infections with multiresistant Gram-positive pathogens. Decades of clinical use mean that this compound is safe to use and may accelerate its evaluation in humans.

1 February 2013 in Experimental Cell Research
Verified
Journal Article
Closed access
IZIdoia G. Zubeldia
Idoia G. Zubeldia
ABAnne-Marie Bleau
Anne-Marie Bleau
MRMiriam Redrado
Miriam Redrado
DSDiego Serrano
Diego Serrano
AAAlice Agliano
Alice Agliano
ACAlfonso Calvo
Alfonso Calvo

1 November 2013 in Infection and Immunity
Verified
Journal Article
Open access
PDF file
PMPau Morey
Pau Morey
CVCristina Viadas
Cristina Viadas
BEBegoña Euba
Begoña Euba
DHDerek W. Hood
Derek W. Hood
MBMontserrat Barberán
Montserrat Barberán
JGJunkal Garmendia
Junkal Garmendia
Nontypeable Haemophilus influenzae (NTHi) is a frequent commensal of the human nasopharynx that causes opportunistic infection in immunocompromised individuals. Existing evidence associates lipooligosaccharide (LOS) with disease, but the specific and relative contributions of NTHi LOS modifications to virulence properties of the bacterium have not been comprehensively addressed. Using NTHi strain 375, an isolate for which the detailed LOS structure has been determined, we compared systematically a set of isogenic mutant strains expressing sequentially truncated LOS. The relative contributions of 2-keto-3-deoxyoctulosonic acid, the triheptose inner core, oligosaccharide extensions on heptoses I and III, phosphorylcholine, digalactose, and sialic acid to NTHi resistance to antimicrobial peptides (AMP), self-aggregation, biofilm formation, cultured human respiratory epithelial infection, and murine pulmonary infection were assessed. We show that opsX , lgtF , lpsA , lic1 , and lic2A contribute to bacterial resistance to AMP; lic1 is related to NTHi self-aggregation; lgtF , lic1 , and siaB are involved in biofilm growth; opsX and lgtF participate in epithelial infection; and opsX , lgtF , and lpsA contribute to lung infection. Depending on the phenotype, the involvement of these LOS modifications occurs at different extents, independently or having an additive effect in combination. We discuss the relative contribution of LOS epitopes to NTHi virulence and frame a range of pathogenic traits in the context of infection.